Don't we forget about biological therapy of hypercholesterolemia with PCSK9-inhibitors?
| Autor: | Ondřej Kyselák, Vladimír Soška |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Statin medicine.drug_class Hypercholesterolemia Familial hypercholesterolemia 030204 cardiovascular system & hematology 03 medical and health sciences 0302 clinical medicine Ezetimibe Internal medicine Internal Medicine Medicine Humans cardiovascular diseases 030212 general & internal medicine PCSK9 Inhibitors Ldl cholesterol business.industry Atherosclerotic cardiovascular disease Anticholesteremic Agents nutritional and metabolic diseases medicine.disease Biological Therapy lipids (amino acids peptides and proteins) Statin therapy Hydroxymethylglutaryl-CoA Reductase Inhibitors Proprotein Convertase 9 Cardiology and Cardiovascular Medicine business medicine.drug |
| Zdroj: | Vnitrni lekarstvi. 67(3) |
| ISSN: | 0042-773X |
| Popis: | In many patients it is difficult to achieve the current very low target LDL-cholesterol levels, recommended for the prevention of atherosclerotic cardiovascular events. If statin therapy or statins in combination with ezetimibe are not sufficient, addition of PCSK9 inhibitors should be considered. PCSK9 inhibitors reduce LDL-CH by an average of 50-60 % and reduce the risk of atherosclerotic cardiovascular events. They are currently reserved for patients with atherosclerotic cardiovascular disease and for patients with familial hypercholesterolaemia, in whom despite intensive hypolipidemic therapy statins with ezetimibe the target LDL-cholesterol value is not reached. In these patients, PCSK9 inhibitors may also be indicated in case of statin intolerance. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|